Recent Company News

• 02:33 AM ET May 19, 2026
  

  Bayer granted Priority Review by FDA for Asundexian in patients after a non-cardioembolic ischemic stroke or transient ischemic attack (€37.83, 0.00)

• 08:42 AM ET May 18, 2026
  

  FDA Grants Priority Review to Supplemental New Drug Application for Bayer's HYRNUO (sevabertinib) (€37.29, -0.42)

• 12:07 AM ET May 16, 2026
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 11:12 AM ET May 15, 2026
  

  Bayer announces that Primary results from the Phase II ARASEC trial show that NUBEQA plus ADT showed a statistically significant improvement in progression-free survival (PFS) and overall survival (OS) in patients with mCSPC (€37.85, -0.33)

• 05:31 PM ET May 14, 2026
  

  Transcript Intelligence: Bayer AG at BMO Global Farm to Market Conference

• 05:03 PM ET May 12, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 10:14 AM ET May 12, 2026
  

  Transcript Intelligence: Bayer AG Q1 Earnings Guidance

• 10:14 AM ET May 12, 2026
  

  Transcript Intelligence: Bayer AG Q1 Earnings Themes

• 10:13 AM ET May 12, 2026
  

  Transcript Intelligence: Bayer AG Q1 Earnings Q&A

• 08:55 AM ET May 12, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market